A recent consensus from the ELN MRD working group recommends WT1 as an important tool in monitoring MRD and stratifying patients with AML especially those who lack a more sensitive marker and thus could influence treatment strategy (2). This evidence concerns the gene WT1 and acute myeloid leukemia.